Autolus Therapeutics (AUTL) confirmed that the U.K. Medicines and Healthcare products Regulatory Agency has granted ...

Company outlined potential for value creation driven by obe-cel across multiple B cell driven malignancies and autoimmune diseases, including acute lymphoblastic leukemia (ALL), lupus nephritis (LN) ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorisation to Autolus ...

Autolus Therapeutics, a UCL spinout company, has received authorisation from the UK Medicines and Healthcare products ...

View Our Latest Report on Autolus Therapeutics Autolus Therapeutics Stock Up 4.5 % AUTL opened at $1.39 on Tuesday. The stock has a market capitalization of $369.87 million, a price-to-earnings ...

Autolus Therapeutics (AUTL) confirmed that the U.K. Medicines and Healthcare products Regulatory Agency has granted conditional marketing authorization for AUCATZYL for the treatment of adult ...

Autolus Therapeutics plc, a biopharmaceutical company focused on next-generation programmed T cell therapies, has announced the upcoming release of its first quarter 2025 financial results and ...

Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today presented ...

The new conditional marketing authorization was granted on April 25 to Autolus Therapeutics (AUTL), the MHRA noted. Published first on TheFly – the ultimate source for real-time, market-moving ...

Autolus Therapeutics plc announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorisation for AUCATZYL (obecabtagene autoleucel ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) late Friday announced it has granted a conditional ...